Royalty Pharma Declares Fourth-Quarter 2021 Dividend
The board of directors of Royalty Pharma (RPRX) has approved a fourth-quarter 2021 dividend of $0.17 per Class A ordinary share. This dividend will be paid on December 15, 2021, to shareholders of record as of November 19, 2021. Royalty Pharma is the largest buyer of biopharmaceutical royalties, funding innovation through partnerships with various biotechnology and pharmaceutical companies. Their portfolio includes royalties from over 45 commercial products, enhancing their financial stability and attractiveness to investors.
- Approved a fourth-quarter 2021 dividend of $0.17 per share.
- Dividend payment indicates strong cash flow and confidence in future performance.
- Royalties from over 45 commercial products contribute to steady revenue.
- None.
NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of
The dividend will be paid on December 15, 2021, to shareholders of record at the close of business on November 19, 2021.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small- and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
What is the dividend amount approved by Royalty Pharma for the fourth quarter of 2021?
When will Royalty Pharma's fourth-quarter dividend be paid?
What is the record date for Royalty Pharma's fourth-quarter dividend?
How many commercial products does Royalty Pharma have royalties from?
